DDInter1050 DDInter1676
Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrenergic antagonist. It is a propanolamine, a cyclic ketone and an aromatic ether. It is a conjugate acid of a levobunolol(1+). It derives from a hydride of a tetralin.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Levobunolol {u} (Compound) resembles {v} (Compound) Propranolol
Levobunolol {u} may lead to a major life threatening interaction when taken with {v} Salbutamol
Levobunolol {u} (Compound) resembles {v} (Compound) Carteolol
Levobunolol {u} (Compound) treats {v} (Disease) glaucoma
Levobunolol {u} (Compound) binds {v} (Gene) ADRB1
Levobunolol {u} (Compound) upregulates {v} (Gene) SSBP2
Levobunolol {u} (Compound) downregulates {v} (Gene) BAG3
Levobunolol {u} (Compound) causes {v} (Side Effect) Eyelid ptosis
Levobunolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gadodiamide
Levobunolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gadoxetic acid
Levobunolol (Compound) resembles Propranolol (Compound)
Levobunolol may lead to a major life threatening interaction when taken with Salbutamol
Levobunolol (Compound) resembles Carteolol (Compound)
Levobunolol (Compound) treats glaucoma (Disease)
Levobunolol (Compound) binds ADRB1 (Gene)
Levobunolol (Compound) upregulates SSBP2 (Gene)
Levobunolol (Compound) downregulates BAG3 (Gene)
Levobunolol (Compound) causes Eyelid ptosis (Side Effect)
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoxetic acid